Welcome to the HIV/AIDS Prevention Research Division

The mission of the HIV/AIDS Prevention Research Division is to develop and evaluate interventions designed to reduce the spread of HIV and other blood-borne infections. The Division promotes the application of scientifically sound data in the development of public health policies designed to respond to the HIV epidemic.


In The News

CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands, 2020


This report describes the demographics of persons tested, newly diagnosed with HIV, and linked to HIV medical care in the United States, Puerto Rico, and U.S. Virgin Islands in 2020. Data presented in this report include HIV test-level data from 60 state and local health departments and 100 community-based organizations reported to CDC through EvaluationWeb® as of September 15, 2021.

HIV and African American Gay and Bisexual Men Web Content and Fact Sheet


This updated web content provides information and statistical data about HIV among African American gay and bisexual men, including a fact sheet that visually displays this information.  

2019 HIV Mortality


The 2019 HIV Mortality Slide Set outlines mortality data from 2019 among persons with HIV and deaths among persons with HIV as an underlying cause of death.

EHE Core Indicators HIV Surveillance Data Tables, NHSS September 2021 and PrEP June 2021


Update on data for monitoring the Ending the HIV Epidemic in the United States initiative reported through CDC through September 2021 and PrEP data through June 2021. Data on HIV diagnoses, linkage to HIV medical care, and PrEP are provided.

Dear Colleague Letter: Updated Clinical Practice Guideline for Preexposure Prophylaxis for HIV Prevention and Clinical Providers Supplement


The updated guideline and supplement reflect the latest science and are intended to help physicians effectively prescribe all FDA-approved pre-exposure prophylaxis (PrEP) medications to patients and increase PrEP use among all people who could benefit. The overall goals of the revisions are to update existing guidance using the current evidence base, incorporate recent and potential FDA actions on PrEP medications, clarify specific aspects of clinical…